AstraZeneca said it expects to have a response from the FDA during the first quarter of 2024
Earlier this week, AstraZeneca announced that the FDA is reviewing an application for its nasal spray flu vaccine FluMist, which would become the first self-administered flu vaccine available across the United States, should it be approved.
FluMist, which is the only nasal spray option to combat the flu, has been on the market in the country since 2003, and is currently only able to be administered by healthcare professionals, AstraZeneca said. The company added that the nasal spray is backed by a study that found that adults ages 18 to 49 are successfully able to give themselves or others the vaccine, including children as young as 2 years old.
AstraZeneca said it expects to have a response from the FDA during the first quarter of 2024, which, if approved, would make the vaccine spray ready by the 2024-25 flu season.
FluMist would be available to be shipped to users' homes in temperature-controlled packaging, AstraZeneca’s Dr. Lisa Glasser told CNN. It could still, however, also be administered at a doctor’s office or pharmacy as well, the outlet said.
Never miss a story — sign up for PEOPLE's free daily newsletter to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
The move by AstraZeneca to make the flu vaccine more accessible comes about as a survey from the National Foundation for Infectious Diseases recently found, per The Hill, that only about 20 percent of U.S. residents are concerned that they or someone close to them could get infected with the flu, COVID-19 or Respiratory Syncytial Virus (RSV) this year.
The study, the outlet said, also determined that about 43 percent of adults do not plan to or are unsure if they will get vaccinated against the flu between 2023 and 2024.
40 percent, meanwhile, said they plan to get vaccinated against COVID-19, while only 40 percent of adults aged 60 years and older said they plan to get vaccinated against RSV.
Last month, Mandy Cohen, who is the Centers for Disease Control and Prevention (CDC) director, said that only 47 percent of adults in the U.S. received a vaccine during the 2022-23 flu season, The Hill reported.
That number was down from the previous 2021-22 season, which saw 49 percent of U.S. adults get vaccinated, the outlet said.
For more People news, make sure to sign up for our newsletter!
Read the original article on People.